keyword
MENU ▼
Read by QxMD icon Read
search

Schizophrenia and negative symptoms

keyword
https://www.readbyqxmd.com/read/28449199/age-at-onset-and-the-outcomes-of-schizophrenia-a-systematic-review-and-meta-analysis
#1
REVIEW
Johanna Immonen, Erika Jääskeläinen, Hanna Korpela, Jouko Miettunen
The aim of this study was to analyse the effect of age at onset on the long-term clinical, social and global outcomes of schizophrenia through a systematic review and a meta-analysis. Original studies were searched from Web of Science, PsycINFO, Pubmed and Scopus, as well as manually. Naturalistic studies with at least a 2-year follow-up were included. Of the 3509 search results, 81 articles fulfilled the inclusion criteria. The meta-analysis was performed in Stata as a random-effect analysis with correlation coefficients between age at onset and the outcomes (categorized into remission, relapse, hospitalization, positive symptoms, negative symptoms, total symptoms, general clinical outcome, employment, social/occupational functioning and global outcome)...
April 27, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28446243/targeting-metabotropic-glutamate-receptors-for-novel-treatments-of-schizophrenia
#2
REVIEW
James Maksymetz, Sean P Moran, P Jeffrey Conn
Support for the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia has led to increasing focus on restoring proper glutamatergic signaling as an approach for treatment of this devastating disease. The ability of metabotropic glutamate (mGlu) receptors to modulate glutamatergic neurotransmission has thus attracted considerable attention for the development of novel antipsychotics. Consisting of eight subtypes classified into three groups based on sequence homology, signal transduction, and pharmacology, the mGlu receptors provide a wide range of targets to modulate NMDAR function as well as glutamate release...
April 26, 2017: Molecular Brain
https://www.readbyqxmd.com/read/28445800/adjunctive-celecoxib-for-schizophrenia-a-meta-analysis-of-randomized-double-blind-placebo-controlled-trials
#3
Wei Zheng, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Norbert Müller, Yu-Ping Ning, Yu-Tao Xiang
Neuroinflammation has been implicated in the neurobiological pathways of schizophrenia. This meta-analysis evaluated the efficacy and tolerability of adjunctive celecoxib as a noncompetitive anti-inflammation drug in treating schizophrenia. Data were searched, extracted, checked and entered into the RevMan (version 5.3) software by two independent investigators. Standardized/weighted mean differences (SMDs/WMDs), risk ratio (RR) and their 95% confidence intervals (CIs) were calculated, as appropriate. Included were 8 randomized controlled trials (RCTs) with a total of 626 patients with schizophrenia including 316 (50...
April 14, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28443355/investigational-dopamine-antagonists-for-the-treatment-of-schizophrenia
#4
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Tae-Youn Jun, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae
Introduction Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D2 receptors. Areas Covered We searched for investigational drugs using the key words 'dopamine' and 'schizophrenia' in American and European clinical trial registers (clinicaltrials...
April 26, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28442912/tumor-necrosis-factor-%C3%AE-and-%C3%AE-genetic-polymorphisms-as-a-risk-factor-in-saudi-patients-with-schizophrenia
#5
Saeed Kadasah, Misbahul Arfin, Sadaf Rizvi, Mohammed Al-Asmari, Abdulrahman Al-Asmari
BACKGROUND: Schizophrenia is one of the most common devastating psychiatric disorders that negatively affects the quality of life and psychosocial functions. Its etiology involves the interplay of complex polygenic influences and environmental risk factors. Inflammatory markers are well-known etiological factors for psychiatric disorders, including schizophrenia. OBJECTIVE: The aim of this study was to investigate the association of proinflammatory cytokine genes, tumor necrosis factor (TNF)-α (-308G/A) and TNF-β (+252A/G) polymorphisms with schizophrenia susceptibility...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28438555/amygdala-activity-associated-with-social-choice-in-mice
#6
Takuma Mihara, Kobina Mensah-Brown, Rosanna Sobota, Robert Lin, Robert Featherstone, Steven J Siegel
Studies suggest that the amygdala is a key region for regulation of anxiety, fear and social function. Therefore, dysfunction of the amygdala has been proposed as a potential mechanism for negative symptoms in schizophrenia. This may be due to NMDA receptor-mediated hypofunction, which is thought to be related to the pathogenesis of schizophrenia. In this study, electroencephalographic amygdala activity was assessed in mice during the three-chamber social test. This activity was also evaluated following exposure to the NMDA receptor antagonist ketamine...
April 21, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28437056/psychotic-and-bipolar-disorders-schizophrenia
#7
Alaina L Edmunds
Schizophrenia is the most common psychotic illness, typically appearing between the late teenage years and the mid-30s. The first episode of psychosis may be preceded by a prodromal period. Schizophrenia symptoms fall into six common symptom clusters: delusions and hallucinations, disorganization of speech, cognitive dysfunction, negative symptoms, affective symptoms, and motor system abnormalities. The diagnosis is based on criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, including exclusion of other possible medical or psychiatric etiologies of psychosis...
April 2017: FP Essentials
https://www.readbyqxmd.com/read/28435992/elevated-plasma-s100b-psychotic-symptoms-and-cognition-in-schizophrenia
#8
Huiqiong Deng, Ramandeep S Kahlon, Satyajit Mohite, Pooja A Amin, Giovana Zunta-Soares, Gabriela D Colpo, Laura Stertz, Gabriel R Fries, Consuelo Walss-Bass, Jair C Soares, Olaoluwa O Okusaga
S100B is a calcium binding protein mainly produced by glial cells. Previous studies have shown elevated levels of S100B in patients with schizophrenia. We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls. We used linear regression to compare S100B between patients and controls. In patients only, we also investigated the relationship between S100B levels and psychotic symptoms (assessed by the Positive and Negative Syndrome Scale), and cognitive function (assessed by the NIH Toolbox Cognition Battery), respectively by calculating Pearson's correlation coefficients...
April 24, 2017: Psychiatric Quarterly
https://www.readbyqxmd.com/read/28434616/impaired-tuning-of-neural-ensembles-and-the-pathophysiology-of-schizophrenia-a-translational-and-computational-neuroscience-perspective
#9
REVIEW
John H Krystal, Alan Anticevic, Genevieve J Yang, George Dragoi, Naomi R Driesen, Xiao-Jing Wang, John D Murray
The functional optimization of neural ensembles is central to human higher cognitive functions. When the functions through which neural activity is tuned fail to develop or break down, symptoms and cognitive impairments arise. This review considers ways in which disturbances in the balance of excitation and inhibition might develop and be expressed in cortical networks in association with schizophrenia. This presentation is framed within a developmental perspective that begins with disturbances in glutamate synaptic development in utero...
May 15, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28433499/changes-in-the-expression-of-metabotropic-glutamate-receptor-5-mglur5-in-a-ketamine-based-animal-model-of-schizophrenia
#10
Dariusz Zurawek, Anna Salerno-Kochan, Marta Dziedzicka-Wasylewska, Agnieszka Nikiforuk, Tomasz Kos, Piotr Popik
It has been shown that the metabotropic glutamate receptor subtype 5 (mGluR5) is functionally associated with the NMDA subtype of the glutamate receptor family (NMDA receptors). These two receptors colocalize in brain regions associated with schizophrenia. Although the role of the NMDA receptor in cognitive and negative symptoms of schizophrenia is well studied, information about the role of mGluR5 receptors in schizophrenia is sparse. In our work, we show that subchronic administration of ketamine, a well-studied, non-competitive antagonist of NMDA receptors, caused cognitive deficits in rats as shown by testing novel object recognition (NOR)...
April 19, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28431868/a-longitudinal-analysis-of-quality-of-life-and-associated-factors-in-older-adults-with-schizophrenia-spectrum-disorder
#11
Carl I Cohen, Aninditha Vengassery, Elena F Garcia Aracena
OBJECTIVES: Self-perceived quality of life (QOL) is an important outcome indicator in schizophrenia and a predictor of symptomatic and functional improvement. This study provides the first large scale longitudinal study of the fluctuations, predictors, and impact of QOL in older adults with schizophrenia spectrum disorder (SSD). METHODS: The sample consisted of 104 community-dwelling persons with SSD aged 55 and over (mean age: 61years) who developed the disorder prior to age 45...
March 7, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28431278/intranasal-oxytocin-does-not-modulate-jumping-to-conclusions-in-schizophrenia-potential-interactions-with-caudate-volume-and-baseline-social-functioning
#12
Fernando Caravaggio, Philip Gerretsen, Wanna Mar, Jun Ku Chung, Eric Plitman, Shinichiro Nakajima, Julia Kim, Yusuke Iwata, Raihaan Patel, M Mallar Chakravarty, Gary Remington, Ariel Graff-Guerrero, Mahesh Menon
BACKGROUND: Patients with schizophrenia (SCZ) tend to sample less information when making a decision, jumping to conclusions (JTC) without sufficient evidence. This "JTC bias" may be a trait marker of the disease and may not improve with antipsychotic treatment. We conducted a double-blind, placebo-controlled trial to test whether intranasal oxytocin could reduce JTC in stable, medicated patients with SCZ and healthy controls (HCs). We also explored whether striatal volume, clinical symptoms, and baseline social functioning (SF) was related to JTC performance...
March 31, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28424430/exploring-non-stationarity-patterns-in-schizophrenia-neural-reorganization-abnormalities-in-the-alpha-band
#13
Pablo Núñez, Jesus Poza, Alejandro Bachiller, Javier Gomez-Pilar, Alba Lubeiro, Vicente Molina, Roberto Hornero
OBJECTIVE: The aim of this paper was to characterize brain non-stationarity during an auditory oddball task in schizophrenia (SCH). The level of non-stationarity was measured in the baseline and response windows of relevant tones in SCH patients and healthy controls. APPROACH: Event-related potentials were recorded from 28 SCH patients and 51 controls. Non-stationarity was estimated in the conventional electroencephalography frequency bands by means of Kullback-Leibler divergence (KLD)...
April 20, 2017: Journal of Neural Engineering
https://www.readbyqxmd.com/read/28421639/cilostazol-adjunctive-therapy-in-treatment-of-negative-symptoms-in-chronic-schizophrenia-randomized-double-blind-placebo-controlled-study
#14
Farzin Rezaei, Bita Mesgarpour, Alireza Jeddian, Atefeh Zeionoddini, Payam Mohammadinejad, Elaheh Salardini, Mona Shahriari, Arefeh Zeinoddini, Shahin Akhondzadeh
OBJECTIVE: To evaluate the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase III, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia. METHODS: Eighty-four in-patients with diagnosis of chronic schizophrenia participated in a randomized, placebo-controlled trial and underwent 8 weeks of treatment with either cilostazol (50 mg twice a day) or placebo as an adjuvant to risperidone. Participants were assessed using the positive and negative syndrome scale (PANSS) at baseline and at weeks 2, 4, 6, and 8...
April 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28421313/association-between-forkhead-box-p2-gene-polymorphism-and-clinical-symptoms-in-chronic-schizophrenia-in-a-chinese-population
#15
Wenwang Rao, Xiangdong Du, Yingyang Zhang, Qiong Yu, Li Hui, Yaqin Yu, Changgui Kou, Guangzhong Yin, Xiaomin Zhu, Lijuan Man, Jair C Soares, Xiang Yang Zhang
The forkhead-box P2 (FOXP2) gene polymorphism has been reported to be involved in the susceptibility to schizophrenia; however, few studies have investigated the association between FOXP2 gene polymorphism and clinical symptoms in schizophrenia. This study investigated whether the FOXP2 gene was associated with the development and symptoms of schizophrenia in relatively genetically homogeneous Chinese population. The FOXP2 rs10447760 polymorphism was genotyped in 1069 schizophrenia inpatients and 410 healthy controls using a case-control design...
April 18, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/28419874/oral-administration-of-a-specific-kynurenic-acid-synthesis-kat-ii-inhibitor-attenuates-evoked-glutamate-release-in-rat-prefrontal-cortex
#16
D M Bortz, H-Q Wu, R Schwarcz, J P Bruno
Cognitive deficits represent core symptoms in schizophrenia (SZ) and predict patient outcome; however, they remain poorly treated by current antipsychotic drugs. Elevated levels of the endogenous alpha7 nicotinic receptor negative allosteric modulator and NMDA receptor antagonist, kynurenic acid (KYNA), are commonly seen in post-mortem tissue and cerebrospinal fluid of patients with SZ. When acutely or chronically elevated in rodents, KYNA produces cognitive deficits similar to those seen in the disease, making down-regulation of KYNA, via inhibition of kynurenine aminotransferase II (KAT II), a potential treatment strategy...
April 15, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28416295/depressive-symptoms-in-schizophrenia-and-dopamine-and-serotonin-gene-polymorphisms
#17
Vjekoslav Peitl, Mario Štefanović, Dalibor Karlović
Although depressive symptoms seem to be frequent in schizophrenia they have received significantly less attention than other symptom domains. As impaired serotonergic and dopaminergic neurotransmission is implicated in the pathogenesis of depression and schizophrenia this study sought to investigate the putative association between several functional gene polymorphisms (SERT 5-HTTLPR, MAO-A VNTR, COMT Val158Met and DAT VNTR) and schizophrenia. Other objectives of this study were to closely examine schizophrenia symptom domains by performing factor analysis of the two most used instruments in this setting (Positive and negative syndrome scale - PANSS and Calgary depression rating scale - CDSS) and to examine the influence of investigated gene polymorphisms on the schizophrenia symptom domains, focusing on depressive scores...
April 14, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28414930/antipsychotics-promote-gabaergic-interneuron-genesis-in-the-adult-rat-brain-role-of-heat-shock-protein-production
#18
Hiroo Kaneta, Wataru Ukai, Hanako Tsujino, Kengo Furuse, Yoshiyasu Kigawa, Masaya Tayama, Takao Ishii, Eri Hashimoto, Chiaki Kawanishi
Current antipsychotics reduce positive symptoms and reverse negative symptoms in conjunction with cognitive behavioral issues with the goal of restoring impaired occupational and social functioning. However, limited information is available on their influence on gliogenesis or their neurogenic properties in adult schizophrenia brains, particularly on GABAergic interneuron production. In the present study, we used young adult subventricular zone (SVZ)-derived progenitor cells expressing proteoglycan NG2 cultures to examine the oligodendrocyte and GABAergic interneuron genesis effects of several kinds of antipsychotics on changes in differentiation function induced by exposure to the NMDA receptor antagonist MK-801...
March 10, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28412921/synthetic-cannabinoids-psychopharmacology-clinical-aspects-and-psy-chotic-onset
#19
Giovanni Martinotti, Rita Santacroce, Duccio Papanti, Yasmine Elgharably, Mariya Prilutskaya, Ornella Corazza
Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. SC are chemically heterogeneous and structurally dissimilar from delta-9-tetrahydrocannabinol, being full agonists of the endocannabinoid system receptors CB1 and CB2. Desired effects include euphoria, talkativeness, feelings of joy and laughter, relaxation. With respect to cannabis, SC intake may also be associated with quicker arise of the effects, shorter duration of action, and larger levels of hangover...
April 13, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28412910/aripiprazole-a-drug-that-displays-partial-agonism-and-functional-selectivity
#20
Erin W Tuplin, Matthew R Holahan
The treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) are a common occurrence. Atypical antipsychotics targeting 5-TH2A and D2 receptors are more effective at treating cognitive and negative symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes...
April 13, 2017: Current Neuropharmacology
keyword
keyword
31727
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"